Beckley Waves

Beckley Waves is a New York-based venture studio and investment firm that builds and funds companies focused on developing care delivery infrastructure for legal psychedelic medicines. Operating within the mental health sector, the organization incubates startups providing safe access to psychedelic care, specialized therapist training, and related healthcare services. Rather than operating as a traditional venture capital fund, the firm utilizes an incubation model to maximize its operational impact on select businesses. To support these venture studio operations and expand its ecosystem, the firm secured $3.3 million in seed funding during early 2023. The active portfolio includes strategic investments and acquisitions across the psychedelic industry, featuring recognizable operating companies such as Beckley Retreats, Fluence, Nue Life, and The Trip Report. Beckley Waves was established in 2021 by co-founders Rock Feilding-Mellen, Neil Markey, and Amanda Feilding.

Beckley Waves is a psychedelic venture studio and investment firm founded in 2021, focused on building the operational infrastructure for the legal, safe, and responsible delivery of psychedelic-assisted treatments. Its mission is to advance mental well-being and foster a thriving psychedelic industry rooted in science, innovation, and compassion by incubating and investing in early-stage companies that develop platforms, services, and care-delivery systems for psychedelic therapies. Beckley Waves supports companies that enhance equitable access to psychedelic medicines and mental health solutions, addressing gaps in treatment availability and regulatory navigation within the emerging psychedelic ecosystem[1][2][3].

The firm primarily invests in pioneering startups that build foundational infrastructure for psychedelic-assisted therapies, including practitioner training programs and psilocybin retreats. Beckley Waves leverages a venture studio model to provide funding, mentorship, and operational support to mission-aligned entrepreneurs and companies, aiming to create a global ecosystem that responsibly integrates psychedelics into clinical, therapeutic, and spiritual settings. Its impact on the startup ecosystem includes accelerating the growth of companies that enable safe, lawful psychedelic treatments and fostering innovation in mental health care delivery[1][2][3].

Beckley Waves was co-founded by Amanda Feilding, a prominent figure in psychedelic research and advocacy with decades of experience through the Beckley Foundation and Beckley Psytech. The company was incorporated in January 2021 in Oxford, UK, and has since raised over $7 million in funding. The idea for Beckley Waves emerged from the need to build scalable, operational infrastructure to support the responsible use of psychedelics, bridging scientific research with practical delivery systems. Early traction includes the establishment of portfolio companies focused on data platforms, marketing, and treatment provider networks within the psychedelic field[1][2][3][5].

Core Differentiators

• Unique Venture Studio Model: Beckley Waves combines incubation, investment, and operational support tailored to the psychedelic sector, enabling early-stage ventures to navigate complex regulatory and market challenges.
• Strong Network and Legacy: Leveraging Amanda Feilding’s pioneering work and the Beckley Foundation’s scientific credibility, the firm benefits from deep expertise and connections in psychedelic research and policy.
• Focus on Infrastructure: Unlike many investors focusing solely on drug development, Beckley Waves targets the broader ecosystem, including care delivery, practitioner training, and patient access platforms.
• Commitment to Ethics and Safety: The firm prioritizes companies dedicated to ethical, legal, and responsible practices that benefit individuals, society, and the environment[1][2][3].

Role in the Broader Tech Landscape

Beckley Waves is riding the global trend of increasing acceptance and legalization of psychedelic-assisted therapies for mental health conditions such as depression, PTSD, and anxiety. The timing is critical as regulatory frameworks evolve and scientific evidence mounts supporting psychedelics’ therapeutic potential. Market forces favor companies that can build scalable, compliant infrastructure to meet growing demand for alternative mental health treatments. Beckley Waves influences the ecosystem by shaping the operational backbone necessary for psychedelics to transition from experimental therapies to mainstream, accessible care options[1][2][3][4].

Quick Take & Future Outlook

Looking ahead, Beckley Waves is poised to expand its portfolio and deepen its support for companies that enhance access to psychedelic therapies globally. Trends such as increased regulatory approvals, growing public acceptance, and advances in digital health platforms will shape its journey. The firm’s influence is likely to grow as it helps establish standardized care models and operational best practices, potentially becoming a key enabler of the psychedelic medicine revolution. Beckley Waves continues Amanda Feilding’s legacy by fostering innovation that integrates psychedelics responsibly into mental health care, promising a transformative impact on wellbeing and consciousness[1][2][3].